Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Bayer
Hoffmann-La Roche
Alume Biosciences, Inc.
Hoffmann-La Roche
Icahn School of Medicine at Mount Sinai
NRG Oncology
Hoffmann-La Roche
AstraZeneca
AstraZeneca
Resilience
Astellas Pharma Inc
Canadian Cancer Trials Group
AstraZeneca
University of Alabama at Birmingham
Merck Sharp & Dohme LLC
AstraZeneca
Peking University People's Hospital
Merck Sharp & Dohme LLC
Akeso
Servier
Federation Francophone de Cancerologie Digestive
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hoffmann-La Roche
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
Mashhad University of Medical Sciences
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
The Methodist Hospital Research Institute
Ain Shams University
University of California, San Diego
Memorial Sloan Kettering Cancer Center
Daiichi Sankyo
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
UNICANCER
Australasian Gastro-Intestinal Trials Group
Stanford University
Fox Chase Cancer Center
Changchun GeneScience Pharmaceutical Co., Ltd.
Alliance for Clinical Trials in Oncology
MacroGenics
Alliance for Clinical Trials in Oncology
UNICANCER
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Henlius Biotech
Shanghai Henlius Biotech
Immune Oncology Research Institute
European Institute of Oncology
Hospices Civils de Lyon
Assiut University
Trans Tasman Radiation Oncology Group